Literature DB >> 18932267

Covert preleukemia driven by MLL gene fusion.

Jan Zuna1, Tatiana Burjanivova, Ester Mejstrikova, Zuzana Zemanova, Katerina Muzikova, Claus Meyer, Sharon W Horsley, Lyndal Kearney, Susan Colman, Hana Ptoszkova, Rolf Marschalek, Ondrej Hrusak, Jan Stary, Mel Greaves, Jan Trka.   

Abstract

Acute leukemia is considered to be a two- or multiple-step process. Although there is a considerable knowledge regarding the character of the "first hit," the nature of the "second hit" remains unanswered in most of the cases including leukemias with MLL gene rearrangement. We demonstrate here a striking sequence of events, which include a covert, protracted preleukemic phase characterized by a dominant MLL/FOXO3A clone with intact myeloid differentiation and the subsequent acquisition of a secondary genetic abnormality, leading to overt lymphoblastic leukemia. Backtracking of the secondary acute lymphoblastic leukemia (sALL) with the MLL rearrangement showed no blasts in the bone marrow (BM) during the protracted preleukemic phase. However, at the same time (more than 1 year before the sALL diagnosis) the MLL/FOXO3A was present in up to 90% of BM cells including myeloid lineage, suggesting that the fusion arose in a multipotent progenitor. To identify potential "second hit" precipitating sALL we compared DNA in preleukemic versus fully leukemic samples. The analysis revealed a 10 Mb gain on 19q13.32 in the sALL, absent in the preleukemic specimen. These data provide insight into the dynamics of leukemogenesis in secondary leukemia with MLL rearrangement.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18932267     DOI: 10.1002/gcc.20622

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

1.  Acute lymphoblastic leukemia with aleukemic prodrome: preleukemic dynamics and possible mechanisms of immunosurveillance.

Authors:  Olga Zimmermannova; Marketa Zaliova; Anthony V Moorman; Halima Al-Shehhi; Eva Fronkova; Zuzana Zemanova; Tomas Kalina; Ajay Vora; Jan Stary; Jan Trka; Ondrej Hrusak; Jan Zuna
Journal:  Haematologica       Date:  2017-03-02       Impact factor: 9.941

2.  Reemergence of translocation t(11;19)(q23;p13.1) in the absence of clinically overt leukemia.

Authors:  Suguru Uemura; Akihiro Tamura; Atsuro Saito; Daiichiro Hasegawa; Nanako Nino; Takehito Yokoi; Teppei Tahara; Aiko Kozaki; Kenji Kishimoto; Toshiaki Ishida; Keiichiro Kawasaki; Takeshi Mori; Noriyuki Nishimura; Minenori Ishimae; Mariko Eguchi; Yoshiyuki Kosaka
Journal:  Int J Hematol       Date:  2017-07-01       Impact factor: 2.490

3.  CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.

Authors:  Fatih M Uckun; Patricia Goodman; Hong Ma; Ilker Dibirdik; Sanjive Qazi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-14       Impact factor: 11.205

Review 4.  Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis.

Authors:  M R Corces-Zimmerman; R Majeti
Journal:  Leukemia       Date:  2014-07-09       Impact factor: 11.528

Review 5.  CircRNAs in hematopoiesis and hematological malignancies.

Authors:  A Bonizzato; E Gaffo; G Te Kronnie; S Bortoluzzi
Journal:  Blood Cancer J       Date:  2016-10-14       Impact factor: 11.037

6.  Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations.

Authors:  Kyle R Salci; Jong-Hee Lee; Sarah Laronde; Steve Dingwall; Rahul Kushwah; Aline Fiebig-Comyn; Brian Leber; Ronan Foley; Arianna Dal Cin; Mickie Bhatia
Journal:  Stem Cells       Date:  2015-06       Impact factor: 6.277

Review 7.  Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia.

Authors:  M Ryan Corces; Howard Y Chang; Ravindra Majeti
Journal:  Front Oncol       Date:  2017-11-06       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.